Age (range), sex
|
26.6 (18 – 38),
male
|
30.5 (21 – 43),
male
|
Symptoms (any), n (%) |
12 (54 %*) |
19 (95
%) |
Respiratory symptoms, n (%)
Cough
Breathlessness
|
8 (36 %*)
7 (88 %)
1 (12%)
|
16 (80 %)
16 (100 %)
2 (12 %)
|
Prior SARS-CoV-2 infection, n (%) |
7 (29 %) |
3 (15
%) |
Number of vaccinations, n (%)
none
at least 1
1 (incomplete)
2 (basic immunization)
3 (boostered)
|
3 (12 %)
21 (88 %)
6 (26 %)
7 (29 %)
8 (33 %)
|
2 (10 %)
18 (90 %)
3 (15 %)
12 (60%)
3 (15 %)
|
Vaccine, n (%)
Moderna (Spikevax®)
Pfizer/BioNTech (Comirnaty®)
Johnson & Johnson (Janssen®)
|
18 (86%)
3 (14%)
0 (0 %)
|
13 (72%)
4 (22%)
1 (6%)
|
Asthma, n (%) |
2 (8%) |
4 (21 %) |
Allergic rhinitis, n (%) |
3 (4%) |
5 (25 %) |
Regular URTI or fever, n (%) |
2 (9 %**) |
1 (5
%) |
Recurrent herpes labialis, n (%) |
5 (22 %**) |
3 (16
%) |